Log in

BidaskClub Lowers Sorrento Therapeutics (NASDAQ:SRNE) to Hold

Last updated on Wednesday, October 21, 2020 | 2020 MarketBeat

Sorrento Therapeutics (NASDAQ:SRNE) was downgraded by equities researchers at BidaskClub from a "buy" rating to a "hold" rating in a report issued on Wednesday, BidAskClub reports.

Several other equities analysts have also commented on the company. Zacks Investment Research upgraded Sorrento Therapeutics from a "hold" rating to a "buy" rating and set a $9.00 price target on the stock in a research note on Saturday, August 29th. HC Wainwright lifted their target price on Sorrento Therapeutics from $24.00 to $30.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Finally, ValuEngine lowered Sorrento Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, July 2nd. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of "Buy" and a consensus target price of $21.00.

Shares of Sorrento Therapeutics stock opened at $8.22 on Wednesday. The firm has a market cap of $2.15 billion, a P/E ratio of -5.04 and a beta of 2.93. The company has a current ratio of 0.60, a quick ratio of 0.58 and a debt-to-equity ratio of 1.83. Sorrento Therapeutics has a 12 month low of $1.45 and a 12 month high of $19.39. The stock's fifty day moving average price is $9.12 and its 200-day moving average price is $6.90.

Sorrento Therapeutics (NASDAQ:SRNE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.02. The firm had revenue of $9.01 million for the quarter, compared to analyst estimates of $7.90 million. Sorrento Therapeutics had a negative return on equity of 490.67% and a negative net margin of 760.19%. Analysts forecast that Sorrento Therapeutics will post 5.13 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Sorrento Therapeutics by 48.7% in the second quarter. Vanguard Group Inc. now owns 9,768,037 shares of the biopharmaceutical company's stock valued at $61,344,000 after purchasing an additional 3,200,338 shares during the last quarter. Cormorant Asset Management LP grew its stake in shares of Sorrento Therapeutics by 30.0% during the second quarter. Cormorant Asset Management LP now owns 6,500,000 shares of the biopharmaceutical company's stock worth $40,820,000 after acquiring an additional 1,500,000 shares during the last quarter. State Street Corp grew its stake in shares of Sorrento Therapeutics by 0.6% during the first quarter. State Street Corp now owns 2,301,587 shares of the biopharmaceutical company's stock worth $4,235,000 after acquiring an additional 14,674 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Sorrento Therapeutics by 7.0% during the first quarter. Geode Capital Management LLC now owns 1,830,666 shares of the biopharmaceutical company's stock worth $3,368,000 after acquiring an additional 120,452 shares during the last quarter. Finally, Coatue Management LLC purchased a new stake in shares of Sorrento Therapeutics during the second quarter worth about $8,478,000. Institutional investors own 24.09% of the company's stock.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc, a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia.

Featured Story: Understanding Specialty Certificates of Deposit

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

7 Stocks That Don’t Care Who Wins the Election

Many investors confuse volatility in an election year with the market performance during an election year. Historically, investors don’t care all that much who wins the election.

There is historical evidence that the market will rise after a Republican wins and dip after a Democrat wins. But that same evidence suggests that those trends flip in the first year of a presidency. It just proves that there’s a difference between campaigning and governing.

What can be different is where investors choose to make their money. It’s very clear that certain sectors perform better under a Republican administration than a Democrat administration. But that’s not the focus of this presentation.

Rather, we’re taking a look at companies, and stocks, that should profit no matter who occupies 1600 Pennsylvania Avenue. Some of these will be familiar names, but we’re trying not to be too obvious. Amazon (NASDAQ:AMZN) is a buy no matter who wins. You don’t need an article to tell you that.

And while I wouldn’t call this a list of “coronavirus stocks” the list has some resemblance. The fact is every major event in our nation’s history has a ripple effect. And technologies that we never imagined would become “a thing” become the most important thing in our lives.

View the "7 Stocks That Don’t Care Who Wins the Election".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.